Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LEROY B VAUGHAN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1366646697
CMS profile
629902
Location
RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$13,193.85

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $13,135.04 11
Ferring Pharmaceuticals Inc. $29.51 1
Melinta Therapeutics, LLC $29.30 1

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LEROY B VAUGHAN

NPI 1366646697 · CMS profile ID 629902

Allopathic & Osteopathic Physicians / Internal Medicine

RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366646697?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LEROY B VAUGHAN, NPI 1366646697, CMS profile ID 629902. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366646697?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). LEROY B VAUGHAN, NPI 1366646697, CMS profile ID 629902. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366646697?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
LEROY B VAUGHAN, NPI 1366646697, CMS profile ID 629902, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1366646697?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $13,193.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $2,875.0012/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204628397 CMS
ABBVIE INC. $124.5911/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204628389 CMS
ABBVIE INC. $7.0011/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204628393 CMS
Ferring Pharmaceuticals Inc. $29.5108/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242088138 CMS
ABBVIE INC. $5.2706/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204628384 CMS
ABBVIE INC. $2,875.0004/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204628381 CMS
ABBVIE INC. $13.9004/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204628377 CMS
ABBVIE INC. $2,875.0003/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204628374 CMS
ABBVIE INC. $123.8203/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204628371 CMS
ABBVIE INC. $4,025.0003/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204628367 CMS
Melinta Therapeutics, LLC $29.3002/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1221035719 CMS
ABBVIE INC. $97.0602/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204628360 CMS
ABBVIE INC. $113.4002/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204628363 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $59.09 3
PY2022 $20.46 1
PY2023 $6,049.96 8
PY2024 $35,628.74 47
PY2025 $13,193.85 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,807,448.32 336
PY2024 Principal investigator $6,183,192.34 199
PY2023 Recipient $1,340.62 4
PY2023 Principal investigator $9,068,826.97 4,189
PY2022 Principal investigator $2,728,925.31 3,261

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

336 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $9,116.02 12/31/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228748130
Principal investigator 1 ModernaTX, Inc. $643.50 12/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965589
Principal investigator 1 ModernaTX, Inc. $3,000.00 12/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965531
Principal investigator 1 ModernaTX, Inc. $102.45 12/23/2025 Non-covered Recipient Entity
Clinical Research Partners, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965455
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285571
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285573
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285575
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285577
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285579
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285581
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285583
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285585
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285587
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285589
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285591
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285593
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285595
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285597
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285599
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285601
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285603
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285605
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285607
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285609
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285613
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285615
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285617
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285619
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285621
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285623
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285625
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285627
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285629
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285631
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285633
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285635
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285637
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285639
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285641
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285643
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285645
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285647
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285649
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285651
Principal investigator 1 Seqirus USA Inc $337.50 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285653
Principal investigator 1 Seqirus USA Inc $337.50 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285655
Principal investigator 1 Seqirus USA Inc $337.50 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285657
Principal investigator 1 Seqirus USA Inc $337.50 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285663
Principal investigator 1 Seqirus USA Inc $677.70 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285667
Principal investigator 1 Seqirus USA Inc $911.25 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285669
Principal investigator 1 Seqirus USA Inc $969.30 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285671
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285677
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285685
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285687
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285689
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285691
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285693
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285695
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285697
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285699
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285701
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285703
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285705
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285707
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285709
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285711
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285713
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285715
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285717
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285719
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285721
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285723
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285725
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285727
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285729
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285731
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285733
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285735
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285737
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285739
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285741
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285743
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285745
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285747
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285749
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285751
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285753
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285755
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285757
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285759
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285761
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285763
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285765
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285767
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285769
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285771
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285773
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285775
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285777
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285779
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285783
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285785
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285787
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285789
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285791
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285793
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285795
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285797
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285799
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285802
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285805
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285807
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285809
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285811
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285813
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285815
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285817
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285819
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285821
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285823
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285825
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285827
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285829
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285831
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285833
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285835
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285837
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285839
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285841
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285843
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285845
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285847
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285849
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285853
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285855
Principal investigator 1 Seqirus USA Inc $2,662.88 12/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285857
Principal investigator 1 PFIZER INC. $88,030.22 12/17/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228745597
Principal investigator 1 ModernaTX, Inc. $68.30 12/16/2025 Non-covered Recipient Entity
Clinical Research Partners, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965471
Principal investigator 1 ModernaTX, Inc. $1,260.00 12/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965485
Principal investigator 1 ModernaTX, Inc. $585.00 12/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965639
Principal investigator 1 ModernaTX, Inc. $58.50 12/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965489
Principal investigator 1 ModernaTX, Inc. $1,146.60 12/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965555
Principal investigator 1 ModernaTX, Inc. $2,866.50 12/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965557
Principal investigator 1 ModernaTX, Inc. $68.30 12/02/2025 Non-covered Recipient Entity
Clinical Research Partners, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965609
Principal investigator 1 ModernaTX, Inc. $76,240.08 11/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965469
Principal investigator 1 ModernaTX, Inc. $3,445.65 11/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965553
Principal investigator 1 ModernaTX, Inc. $904.02 11/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965569
Principal investigator 1 ModernaTX, Inc. $15,656.52 11/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965573
Principal investigator 1 ModernaTX, Inc. $715.00 11/26/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965467
Principal investigator 1 PFIZER INC. $3,000.00 11/26/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228712748
Principal investigator 1 PFIZER INC. $3,491.40 11/26/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228738129
Principal investigator 1 Seqirus USA Inc $1,282.20 11/21/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810159
Principal investigator 1 Seqirus USA Inc $352.35 11/21/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810164
Principal investigator 1 ModernaTX, Inc. $204.90 11/19/2025 Non-covered Recipient Entity
Clinical Research Partners, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965481
Principal investigator 1 PFIZER INC. $234.00 11/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228723304
Principal investigator 1 PFIZER INC. $303.00 11/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228728073
Principal investigator 1 PFIZER INC. $292.50 11/18/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228729115
Principal investigator 1 ModernaTX, Inc. $175.50 11/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965581
Principal investigator 1 ModernaTX, Inc. $1,111.50 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965583
Principal investigator 1 PFIZER INC. $303.00 11/12/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228728037
Principal investigator 1 PFIZER INC. $11.70 11/12/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228728255
Principal investigator 1 PFIZER INC. $75.75 11/12/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228728631
Principal investigator 1 PFIZER INC. $8,000.00 11/04/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228713581
Principal investigator 1 PFIZER INC. $426.60 11/04/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228724902
Principal investigator 1 PFIZER INC. $426.60 11/04/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228725028
Principal investigator 1 PFIZER INC. $426.60 11/04/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228725236
Principal investigator 1 PFIZER INC. $426.60 11/04/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228731099
Principal investigator 1 PFIZER INC. $426.60 11/04/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228732300
Principal investigator 1 PFIZER INC. $426.60 11/04/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228735906
Principal investigator 1 PFIZER INC. $426.60 11/04/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228735911
Principal investigator 1 PFIZER INC. $426.60 11/04/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY ADULT PARTICIPANTS No dispute reported 06/30/2026 1228736357
Principal investigator 1 Seqirus USA Inc $3,419.20 10/31/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810148
Principal investigator 1 Seqirus USA Inc $939.60 10/31/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810155
Principal investigator 1 ModernaTX, Inc. $20.00 10/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965433
Principal investigator 1 ModernaTX, Inc. $7,140.00 10/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965473
Principal investigator 1 ModernaTX, Inc. $191.10 10/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965517
Principal investigator 1 ModernaTX, Inc. $598.68 10/29/2025 Non-covered Recipient Entity
Clinical Research Partners, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965537
Principal investigator 1 ModernaTX, Inc. $4,006.60 10/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965625
Principal investigator 1 ModernaTX, Inc. $105.30 10/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965633
Principal investigator 1 ModernaTX, Inc. $3,616.08 10/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965449
Principal investigator 1 ModernaTX, Inc. $15,216.30 10/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965493
Principal investigator 1 ModernaTX, Inc. $19,142.50 10/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965571
Principal investigator 1 ModernaTX, Inc. $1,500.00 10/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965453
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965431
Principal investigator 1 Seqirus USA Inc $500.00 10/22/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285665
Principal investigator 1 Seqirus USA Inc $1,880.00 10/22/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285675
Principal investigator 1 Seqirus USA Inc $5,000.00 10/22/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285681
Principal investigator 1 ModernaTX, Inc. $3,200.00 10/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965429
Principal investigator 1 PFIZER INC. $4,800.00 10/15/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228741713
Principal investigator 1 ModernaTX, Inc. $4,000.00 10/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965425
Principal investigator 1 ModernaTX, Inc. $750.00 10/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965427
Principal investigator 1 ModernaTX, Inc. $500.00 10/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965463
Principal investigator 1 Seqirus USA Inc $8,000.00 10/03/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285683
Principal investigator 1 ModernaTX, Inc. $15,024.90 09/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965437
Principal investigator 1 ModernaTX, Inc. $1,111.99 09/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965563
Principal investigator 1 ModernaTX, Inc. $210.00 09/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965629
Principal investigator 1 ModernaTX, Inc. $33,307.95 09/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965635
Principal investigator 1 Seqirus USA Inc $5,000.00 09/29/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285679
Principal investigator 1 PFIZER INC. $10,907.00 09/26/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228760523
Principal investigator 1 PFIZER INC. $8,196.88 09/24/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228759968
Principal investigator 1 Seqirus USA Inc $111.30 09/12/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285659
Principal investigator 1 Seqirus USA Inc $177.19 09/12/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285661
Principal investigator 1 Seqirus USA Inc $1,183.50 09/12/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185285673
Principal investigator 1 ModernaTX, Inc. $480.00 09/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965541
Principal investigator 1 ModernaTX, Inc. $1,000.00 09/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965591
Principal investigator 1 ModernaTX, Inc. $500.00 09/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965593
Principal investigator 1 ModernaTX, Inc. $135.00 09/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965595
Principal investigator 1 ModernaTX, Inc. $2,415.00 09/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965483
Principal investigator 1 ModernaTX, Inc. $70.20 09/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965491
Principal investigator 1 ModernaTX, Inc. $127.40 09/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965599
Principal investigator 1 ModernaTX, Inc. $53.30 09/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965631
Principal investigator 1 ModernaTX, Inc. $8,500.00 08/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965499
Principal investigator 1 ModernaTX, Inc. $21,127.81 08/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965545
Principal investigator 1 ModernaTX, Inc. $29,096.60 08/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965579
Principal investigator 1 ModernaTX, Inc. $325.00 08/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965615
Principal investigator 1 ModernaTX, Inc. $15,407.70 08/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965623
Principal investigator 1 ModernaTX, Inc. $177.84 08/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005151
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965621
Principal investigator 1 PFIZER INC. $5,118.09 08/14/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228761699
Principal investigator 1 ModernaTX, Inc. $105.30 08/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965507
Principal investigator 1 ModernaTX, Inc. $191.10 08/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965561
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,600.00 08/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185538737
Principal investigator 1 PFIZER INC. $289.92 08/01/2025 Non-covered Recipient Entity
Clinical Research Partners
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228712744
Principal investigator 1 PFIZER INC. $131.75 08/01/2025 Non-covered Recipient Entity
Clinical Research Partners
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228712746
Principal investigator 1 PFIZER INC. $757.50 08/01/2025 Non-covered Recipient Entity
Clinical Research Partners
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228712914
Principal investigator 1 PFIZER INC. $757.50 08/01/2025 Non-covered Recipient Entity
Clinical Research Partners
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228712916
Principal investigator 1 PFIZER INC. $131.75 08/01/2025 Non-covered Recipient Entity
Clinical Research Partners
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228713366
Principal investigator 1 PFIZER INC. $289.92 08/01/2025 Non-covered Recipient Entity
Clinical Research Partners
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228713583
Principal investigator 1 PFIZER INC. $3,412.80 07/29/2025 Non-covered Recipient Entity
Clinical Research Partners
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228714130
Principal investigator 1 ModernaTX, Inc. $2,500.00 07/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965435
Principal investigator 1 ModernaTX, Inc. $1,914.25 07/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965443
Principal investigator 1 ModernaTX, Inc. $16,679.85 07/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965565
Principal investigator 1 ModernaTX, Inc. $904.02 07/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965575
Principal investigator 1 ModernaTX, Inc. $4,038.54 07/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965587
Principal investigator 1 ModernaTX, Inc. $500.00 07/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965497
Principal investigator 1 PFIZER INC. $1,734.37 07/16/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228764625
Principal investigator 1 ModernaTX, Inc. $611.00 07/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005159
Principal investigator 1 ModernaTX, Inc. $500.00 07/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005163
Principal investigator 1 ModernaTX, Inc. $5,200.00 06/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005095
Principal investigator 1 ModernaTX, Inc. $904.02 06/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965447
Principal investigator 1 ModernaTX, Inc. $12,096.48 06/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965459
Principal investigator 1 ModernaTX, Inc. $8,805.55 06/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965465
Principal investigator 1 ModernaTX, Inc. $41,143.63 06/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965559
Principal investigator 1 ModernaTX, Inc. $14,469.84 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965457
Principal investigator 1 ModernaTX, Inc. $904.02 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965521
Principal investigator 1 ModernaTX, Inc. $31,393.70 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965549
Principal investigator 1 ModernaTX, Inc. $87,847.21 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965619
Principal investigator 1 ModernaTX, Inc. $19.76 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005103
Principal investigator 1 ModernaTX, Inc. $1,950.00 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005119
Principal investigator 1 ModernaTX, Inc. $20,025.76 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005125
Principal investigator 1 ModernaTX, Inc. $270.00 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005143
Principal investigator 1 ModernaTX, Inc. $16,588.25 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965567
Principal investigator 1 PFIZER INC. $6,036.81 06/14/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228777768
Principal investigator 1 ModernaTX, Inc. $7,026.50 06/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005085
Principal investigator 1 ModernaTX, Inc. $770.77 06/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005135
Principal investigator 1 ModernaTX, Inc. $84,511.24 05/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965461
Principal investigator 1 ModernaTX, Inc. $1,808.04 05/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965523
Principal investigator 1 ModernaTX, Inc. $65,850.20 05/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965547
Principal investigator 1 ModernaTX, Inc. $15,579.96 05/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965627
Principal investigator 1 ModernaTX, Inc. $35,212.32 05/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005109
Principal investigator 1 ModernaTX, Inc. $156,371.36 05/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005111
Principal investigator 1 ModernaTX, Inc. $12,949.02 05/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005137
Principal investigator 1 PFIZER INC. $1,703.61 05/28/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228765350
Principal investigator 1 ModernaTX, Inc. $3,177.20 05/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005129
Principal investigator 1 ModernaTX, Inc. $715.00 05/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965477
Principal investigator 1 ModernaTX, Inc. $1,154.40 05/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965519
Principal investigator 1 ModernaTX, Inc. $495.00 05/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005155
Principal investigator 1 ModernaTX, Inc. $1,100.00 05/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965501
Principal investigator 1 ModernaTX, Inc. $4,500.00 05/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965543
Principal investigator 1 PFIZER INC. $8,129.92 05/14/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228772121
Principal investigator 1 ModernaTX, Inc. $105.00 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965487
Principal investigator 1 PFIZER INC. $4,300.59 05/06/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228766013
Principal investigator 1 ModernaTX, Inc. $86,906.95 04/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965533
Principal investigator 1 ModernaTX, Inc. $1,808.04 04/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965539
Principal investigator 1 ModernaTX, Inc. $16,613.52 04/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965617
Principal investigator 1 ModernaTX, Inc. $46,771.92 04/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005123
Principal investigator 1 ModernaTX, Inc. $34,530.72 04/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005127
Principal investigator 1 ModernaTX, Inc. $75,416.16 04/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005161
Principal investigator 1 ModernaTX, Inc. $715.00 04/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965509
Principal investigator 1 PFIZER INC. $13,770.55 04/16/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228795968
Principal investigator 1 ModernaTX, Inc. $715.00 04/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005153
Principal investigator 1 PFIZER INC. $9,287.40 04/08/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228778847
Principal investigator 1 ModernaTX, Inc. $450.00 04/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005089
Principal investigator 1 ModernaTX, Inc. $540.00 04/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005107
Principal investigator 1 ModernaTX, Inc. $15,312.00 03/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965445
Principal investigator 1 ModernaTX, Inc. $71,592.95 03/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965451
Principal investigator 1 ModernaTX, Inc. $76.56 03/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965475
Principal investigator 1 ModernaTX, Inc. $36,271.95 03/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965479
Principal investigator 1 ModernaTX, Inc. $904.02 03/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965603
Principal investigator 1 ModernaTX, Inc. $34,530.72 03/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005093
Principal investigator 1 ModernaTX, Inc. $8,947.68 03/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005105
Principal investigator 1 ModernaTX, Inc. $43,037.28 03/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005121
Principal investigator 1 ModernaTX, Inc. $8,892.00 03/20/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965601
Principal investigator 1 PFIZER INC. $10,017.42 03/14/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228797973
Principal investigator 1 ModernaTX, Inc. $1,000.00 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965503
Principal investigator 1 ModernaTX, Inc. $24,752.00 03/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005087
Principal investigator 1 ModernaTX, Inc. $221.00 02/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005157
Principal investigator 1 ModernaTX, Inc. $7,879.30 02/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965505
Principal investigator 1 ModernaTX, Inc. $17,092.02 02/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965511
Principal investigator 1 ModernaTX, Inc. $7,656.00 02/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965515
Principal investigator 1 ModernaTX, Inc. $12,414.20 02/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965527
Principal investigator 1 ModernaTX, Inc. $93,903.45 02/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965529
Principal investigator 1 ModernaTX, Inc. $4,520.10 02/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965597
Principal investigator 1 ModernaTX, Inc. $65,949.00 02/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965605
Principal investigator 1 ModernaTX, Inc. $71,592.95 02/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965607
Principal investigator 1 ModernaTX, Inc. $2,015.52 02/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005097
Principal investigator 1 ModernaTX, Inc. $46,297.68 02/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005113
Principal investigator 1 ModernaTX, Inc. $63,912.00 02/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005139
Principal investigator 1 ModernaTX, Inc. $35,969.50 02/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005147
Principal investigator 1 ModernaTX, Inc. $519.09 02/26/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005091
Principal investigator 1 PFIZER INC. $37,989.75 02/22/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228761374
Principal investigator 1 PFIZER INC. $4,095.08 02/05/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228719569
Principal investigator 1 ModernaTX, Inc. $18,699.46 01/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005101
Principal investigator 1 PFIZER INC. $25,945.52 01/30/2025 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1228801697
Principal investigator 1 ModernaTX, Inc. $1,000.00 01/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252965495
Principal investigator 1 ModernaTX, Inc. $5,083.00 01/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005081
Principal investigator 1 ModernaTX, Inc. $47,263.45 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965439
Principal investigator 1 ModernaTX, Inc. $9,455.16 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965441
Principal investigator 1 ModernaTX, Inc. $19,862.72 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965513
Principal investigator 1 ModernaTX, Inc. $45,332.70 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965525
Principal investigator 1 ModernaTX, Inc. $7,560.30 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965535
Principal investigator 1 ModernaTX, Inc. $1,808.04 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965551
Principal investigator 1 ModernaTX, Inc. $26,799.50 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965613
Principal investigator 1 ModernaTX, Inc. $7,809.12 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965637
Principal investigator 1 ModernaTX, Inc. $54,112.16 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005131
Principal investigator 1 ModernaTX, Inc. $31,398.64 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005133
Principal investigator 1 ModernaTX, Inc. $41,724.62 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005141
Principal investigator 1 ModernaTX, Inc. $2,697.24 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005145
Principal investigator 1 ModernaTX, Inc. $6,046.56 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005149
Principal investigator 1 ModernaTX, Inc. $68.30 01/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965611
Principal investigator 1 ModernaTX, Inc. $2,457.00 01/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965585
Principal investigator 1 ModernaTX, Inc. $1,000.00 01/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005083
Principal investigator 1 ModernaTX, Inc. $135.00 01/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005115
Principal investigator 1 ModernaTX, Inc. $2,250.00 01/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005117
Principal investigator 1 ModernaTX, Inc. $68.30 01/13/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252965577
Principal investigator 1 ModernaTX, Inc. $1,170.00 01/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005099